PharMida will develop gold nanoparticle-drug combinations.



Midatech Group has formed a new drug development subsidiary, PharMida. Formation of this Basel-based unit follows an investment by a group of Switzerland-based private investors into Midatech. PharMida will be headed by Fritz R. Buhler, M.D., as chairman and Jan Mous, Ph.D., as CEO.


The mandate of PharMida is to develop a strong portfolio of clinically validated gold nanoparticle-drug combinations. Furthermore, PharMida will manage in-house drug development, commercial partnerships, and out-licensing opportunities in order to leverage a collection of already existing and promising Midatech products or product lines.








This site uses Akismet to reduce spam. Learn how your comment data is processed.